论文部分内容阅读
应用酶联免疫吸附法检测了 38例原发性肝癌 (PHC)患者血清sICAM - 1含量 ,结果表明 :(1)PHC患者血清sICAM - 1水平明显高于健康对照 ,肿瘤直径≥ 5cm或结节≥ 3个组血清sICAM - 1水平高于肿瘤直径 <5cm或结节 <3个组 ,静脉癌栓形成组高于无静脉癌栓形成组(P均小于 0 .0 0 1) ;(2 )PHC患者血清sICAM - 1水平与血清Bil-T、AST含量呈明显正相关 (P <0 .0 5) ,而与血清AFP含量无明显正相关 (P >0 .0 5)。提示sICAM - 1参与PHC的发病过程 ,血清sICAM - 1水平与PHC病情发展与预后关系密切 ,可作为PHC患者监测病情和判断预后的良好指标。
Serum sICAM-1 levels in 38 patients with primary liver cancer (PHC) were detected by enzyme-linked immunosorbent assay. The results showed that: (1) Serum sICAM-1 levels in PHC patients were significantly higher than those in healthy controls, with tumor diameters ≥ 5cm or nodules. Serum sICAM-1 levels in three groups were higher than those with tumor diameter <5cm or nodules <3 groups, and those in venous tumor embolus formation group were higher than those without venous tumor embolus formation group (P all less than 0.010); (2) Serum sICAM-1 levels were positively correlated with serum Bil-T and AST levels in PHC patients (P<0.05), but not significantly correlated with serum AFP levels (P>0.05). It is suggested that sICAM-1 is involved in the pathogenesis of PHC. Serum sICAM-1 level is closely related to the development and prognosis of PHC, and it can be used as a good indicator of PHC patient’s condition monitoring and prognosis.